Marketing

EQRx builds cancer drug pipeline as plans to challenge big pharma take shape

The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.

By Kristin Jensen • Oct. 27, 2020

Facing vaccine doubts, US grapples with building confidence in coronavirus shots

The CDC, for example, doesn't support vaccine mandates for healthcare workers or essential employees, an agency official told experts convened by the FDA Thursday.

By Jonathan Gardner • Oct. 22, 2020

Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales

Under a deal reached with the Department of Justice, Purdue faces fines and a forfeiture worth more than $5 billion — the largest penalties ever for a drug company.

By Jacob Bell • Oct. 21, 2020

Sponsored by Veeva Crossix

Doctors are consumers too! How DTC media impacts HCPs

The findings have implications for how pharma teams should think about their DTC and HCP efforts — they are no longer two separate marketing channels.

Nestlé​ makes newly acquired Aimmune a stand-alone unit, appoints new CEO

Andrew Oxtoby, formerly chief commercial officer at the peanut allergy drugmaker, will take over as head of the new Nestlé business.

By Kristin Jensen • Oct. 14, 2020

FDA moves to pull preterm birth drug from market

AMAG Pharma, the maker of Makena, said the company disagreed with the FDA's proposal and plans to evaluate its options following a failed study.

By Kristin Jensen • Oct. 07, 2020

Sponsored by IQVIA

Achieving success in pharma marketing: The need for a personalized, omnichannel approach

Personalized, insight-driven omnichannel marketing has never been more beneficial or important. 

After setback in the US, Galapagos' main drug finds success elsewhere

A month after the FDA surprisingly rejected the rheumatoid arthritis drug, called filgotinib, it's been cleared by regulators in Europe and Japan.

By Jacob Bell • Sept. 28, 2020

Health insurer sues Indivior over 'profit protection scheme'

Centene aims to recoup money it paid for Indivior's Suboxone product, alleging the drugmaker devised a plan to box out generic competitors.

By Samantha Liss • UPDATED: Sept. 23, 2020 at 11:47 a.m.

Cigna rebrands health services division, including Express Scripts, as Evernorth

The change, which has been in the works since before the pandemic, is the next step in integrating the companies' business since their merger in 2018.

By Rebecca Pifer • Sept. 16, 2020

Hospitals urge HHS to step in on 340B fight with drugmakers

The dispute stems from drugmakers deciding to stop giving 340B discounts to contract pharmacies, which many hospitals use.

By Shannon Muchmore • Sept. 09, 2020

Thermo Fisher deal for Qiagen falls apart after companies fail to secure investor backing

Thermo Fisher had raised its bid for Qiagen to about $12.5 billion, but less than half of the company's shares were tendered by the offer's expiration Monday.

By Nick Paul Taylor , Maria Rachal , Greg Slabodkin • UPDATED: Aug. 13, 2020 at 11:39 a.m.

Bristol Myers pledges to spend $300M on addressing racial, health disparities

The drugmaker aims to double Black and Latinx representation in its executive ranks, among other commitments.

By Kristin Jensen • Aug. 12, 2020

First liquid biopsy test that uses advanced gene sequencing approved by FDA

The test, developed by Guardant Health, combines next-generation sequencing with a cancer blood test.

By Susan Kelly • Aug. 10, 2020

Amarin decides to go it alone in Europe, as uncertainty clouds heart drug's US future

Chief executive John Thero said the company decided against "multiple proposals" for sales partnerships on Vascepa in Europe. Doing so, however, keeps the pressure on Amarin to deliver.

By Ben Fidler • Aug. 04, 2020

Biogen points to COVID-19 for disappointing drug launch

Sales of Vumerity, a key new product in Biogen's plan to bolster its multiple sclerosis drug business, have been slow since it launched in December.

By Jacob Bell • July 22, 2020

Ohio sues Express Scripts for overcharging state pension fund

"We want our money back," attorney general Dave Yost said, arguing Express Scripts "egregiously charged for services it didn't deliver." It's the latest action taken by the state against pharmacy benefit managers. 

By Samantha Liss • July 15, 2020

AbbVie's 'drip-feed' of patents shields top cancer drug from competition, group says

More than seven dozen patents have been granted for Imbruvica in the U.S., helping AbbVie create a legal defense that could protect the drug until 2036. 

By Kristin Jensen • July 15, 2020

Sponsored by Crossix

4 months with COVID-19: Impact on US health and media behaviors

To help pharmaceutical companies navigate the volatile industry landscape, Crossix has continued to monitor country-wide health and media behaviors.

Providers, insurers back ad campaign urging patients to stop 'medical distancing'

Since the pandemic's onset in the United States, health officials have been concerned about the consequences of routine and preventive care being delayed or put off entirely. Providers also fear further revenue loss.

By Shannon Muchmore • July 08, 2020

Novartis to pay $678M to settle claims over 'sham' doctor events

The Swiss drugmaker admitted to hosting lavish dinners and events that were intended to convince doctors to prescribe Novartis heart and diabetes drugs.

By Ned Pagliarulo • July 02, 2020

Gilead pricing suggests it will make a business out of COVID-19 drug

Even at the lower end of its price range, remdesivir could earn Gilead a billion dollars. How well the drug's price is received will be an important test for other companies working on coronavirus treatments.

By Jacob Bell • June 30, 2020

Gilead sets price for COVID-19 drug remdesivir

A typical course of treatment with remdesivir will cost between $2,340 and $3,120 in the U.S., a price range that likely ensures Gilead earns a profit on sales of the drug.

By Ned Pagliarulo • June 29, 2020

Sponsored by IQVIA

Promotional deployment during COVID-19: Quarantine and re-entry

The time is now to shift promotional efforts from live to virtual engagement channels.

Pandemic pushes FDA to 'accelerate' real-world evidence efforts, Hahn says

The agency has grappled with how to use real-world data in regulating drugs and medical devices, but is now leaning on it to update emergency use authorizations, FDA chief Stephen Hahn said.

By Maria Rachal • June 19, 2020